1. A humanized monoclonal antibody that binds to Shiga toxin protein, comprising a constant region and a murine variable region, wherein said constant region contains at least part of a human immunoglobulin constant region and said murine variable region contains at least part of a murine immunoglobulin variable region as shown in Figure 3 (SEQ ID NO: 21) or Figure 6 (SEQ ID NO: 42), wherein the antibody specifically reacts with Stx1 or Stx2 antigen.

32. A humanized monoclonal antibody that binds to a Shiga toxin protein comprising a human immunoglobulin constant region and a variable region,

wherein the variable region comprises amino acid sequences selected from the group consisting of amino acids 31-35 of SEQ ID NO: 44, amino acids 50-66 of SEQ ID NO: 44, amino acids 99-108 of SEQ ID NO: 44, amino acids 24-40 of SEQ ID NO: 42, amino acids 56-62 of SEQ ID NO: 42, and amino acids 95-103 of SEQ ID NO:42.

33. A fragment of the antibody of claim 32 wherein the fragment binds a Shiga toxin protein.

34. The humanized monoclonal antibody of claim 32 wherein the human constant region is selected from the group consisting of IgG, IgA and IgM.

35. The humanized monoclonal antibody of claim 32 wherein the human constant region is IgG.

36. The humanized monoclonal antibody of claim 32 wherein the human constant region is IgG1-kappa.

37. The humanized monoclonal antibody of claim 32 wherein the variable region comprises the amino acid sequence of SEQ ID NO: 44.

38. The humanized monoclonal antibody of claim 32 wherein the variable region comprises he amino acid sequence of SEQ ID NO: 42.

39. A pharmaceutical composition comprising an antibody of claim 32 and a pharmaceutically acceptable carrier or diluent.

40. A pharmaceutical composition comprising an antibody fragment of claim 32 and a pharmaceutically acceptable carrier or diluent.

Please add the following new claims 42-43.

42. The humanized monoclonal antibody of claim 20, wherein the variable region comprises amino acid sequences selected from the group consisting of amino acids 31-35 of SEQ ID NO: 44, amino acids 50-66 of SEQ ID NO: 44, amino acids 99-108 of SEQ ID NO: 44, amino acids 24-40 of SEQ ID NO: 42, amino acids 56-62 of SEQ ID NO: 42, and amino acids 95-103 of SEQ ID NO:42.

E3

43. The humanized monoclonal antibody of claim 1, wherein the human immunoglobulin constant region is as shown in Figure 3 (SEQ ID NO: 19) or Figure 6 (SEQ ID NO: 44).

REMARKS

As an initial matter, Applicants request that the attorney docket number in this case be changed from "04995.0032-0" to -- 56273/ (71758) --. The Examiner is thanked in advance for attention to this detail.

Support for the claim amendments can be found throughout the instant application including the Drawings and claims as filed originally.

Claim 1 has been amended to point out more specifically that the recited variable region is murine. The claim has also been amended to reference specific amino acid sequence for the specified antibody variable regions.

Claims 1 and 32-40 have been amended to improve language and/or dependency.